Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers

Yahoo Finance00:48

Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $11

Futu NewsDec 11 22:33 · Ratings

Promising Developments and Positive Outlook for Recursion Pharmaceuticals Drive Buy Rating

TipRanksDec 11 21:35 · Ratings

Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target

BenzingaDec 11 21:26 · Ratings

Recursion Pharmaceuticals Analyst Ratings

BenzingaDec 11 21:25 · Ratings

TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating

Futu NewsDec 11 20:31 · Ratings